At a glance
ClinicalIndex Comparison Record- ✓Primary lesion maximum diameter ≤4 cm for single fraction SRS or ≤7 cm for multifraction therapy
- ✓Candidate for SRS within ±30 days of surgical resection
- ✓Documented history of malignancy
- ✓No radiographic evidence of leptomeningeal disease
- ✕Prior radiation therapy to the brain for any reason
- ✕Primary tumor is small-cell lung cancer, lymphoma, leukemia, or multiple myeloma
- ✕Pregnant or breast-feeding females
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Trial of Pre-Operative Stereotactic Radiosurgery (SRS) Versus Post-Operative SRS for Brain Metastases
In Brief
A Phase 3 clinical trial evaluating Quality-of-Life Assessment, Questionnaire Administration, and 1 other intervention for Malignant Neoplasm and Metastatic Malignant Neoplasm in the Brain. Currently recruiting, targeting 180 participants across 1 site.
Detailed Summary
This phase III trial studies stereotactic radiosurgery (SRS) before surgery to see how well it works compared with SRS after surgery in treating patients with cancer that has spread to the brain (brain metastases). SRS is the delivery of focused, high-dose radiation given in a single session to the tumors, with a minimal dose given to uninvolved areas of the brain.
Study Details
Timeline
Interventions
Ancillary studies
Ancillary studies
Undergo SRS